Tag: renal denervation

ReCor appoints Lara Barghout to lead commercialisation of Paradise renal denervation...

ReCor Medical and its parent company Otsuka Medical Devices have announced the appointment of Lara Barghout as president and chief executive officer of ReCor. Barghout...

Otsuka Medical Devices and ReCor Medical submit premarket approval of Paradise...

  Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the premarket approval (PMA) application to the US Food and Drug...

ReCor Medical announces consistent reduction of blood pressure in pooled analysis...

ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other...

Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The late-breaking data were presented at the...

TCT 2022 hears “important data” from renal denervation trials

Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September, Boston, USA), “confirm that ultrasound...
ultrasound renal denervation

Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study

ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial...

SoniVie announces successful procedure with Tivus system on first patient enrolled...

SoniVie today announced that on 30 May this year the first patient was treated with its renal artery denervation Tivus therapeutic intravascular ultrasound technology, as...
SonieVie

SoniVie receives FDA IDE approval for pilot study to treat hypertension...

SoniVie recently announced that on 5 May 2022 the US Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its REDUCED1...
EuroPCR

EuroPCR 2022: Studies underscore potential of renal denervation as an adjunctive...

Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscore the potential of renal denervation as an adjunctive therapy to treat hypertension,...

Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study

Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during...
popular

Vascular News’ top 10 most popular stories of September 2021

September's top 10 features five-year ACST-2 results, a new tool to assess amputation risk following popliteal vascular injury, and an interview highlighting the questions...

EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal...

Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating that renal denervation with the Medtronic Symplicity renal denervation system was...

Global SYMPLICITY Registry shows renal denervation lowered blood pressure in patients...

Medtronic has reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity renal denervation system...

Virtual ACC: Renal denervation bests sham control to safely lower blood...

Three months after undergoing renal denervation, patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared...

TARGET BP I trial enrols its first patient

The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use...

EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation

Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Medtronic) is associated with a reduction in subclinical atrial fibrillation in...

The resurgence of renal denervation

More than ever before, arterial hypertension represents one of the greatest health threats and challenges for both patients and treating physicians. With the new...

US FDA approve new study of Medtronic’s Spyral renal denervation system

The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with hypertension who...
RADIANCE-HTN SOLO Paradise system

Otsuka Medical Devices, Otsuak Holdings, and ReCor Medical to merge

Otsuka Holdings, Otsuka Medical Devices, and ReCor Medical have signed a merger agreement pursuant to which Otsuka Holdings will acquire the remaining shares in...

FDA approves RADIANCE-II study of Paradise ultrasound denervation system

The RADIANCE-II study of the Paradise Ultrasound Denervation System (ReCor Medical) for the treatment of hypertension has been approved by the US Food &...
RADIANCE-HTN ReCor Medical

ReCor Medical completes RADIANCE-HTN SOLO hypertension study

ReCor Medical announced today randomisation of its 146th, and final, subject in the SOLO cohort of its RADIANCE-HTN study. RADIANCE-HTN, ReCor's study of its Paradise...

From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal...

It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study...

ESC 2017: MobiusHD implant shown to reduce resistant hypertension

The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory...